Safety Study Finds Increased Lung Blood Clots, Death In Certain Xeljanz Patients

(February 26, 2019, 11:53 AM EST) -- SILVER SPRING, Md. — The Food and Drug Administration on Feb. 25 said a safety clinical trial found an increased risk of pulmonary blood clots and death from Xeljanz when patients with rheumatoid arthritis (RA) take 10 milligrams of the drug twice a day....

Related Sections